Literature DB >> 3966636

Barrett's esophagus: its prevalence and association with adenocarcinoma in patients with symptoms of gastroesophageal reflux.

M G Sarr, S R Hamilton, G C Marrone, J L Cameron.   

Abstract

The pathologic reports of all 1,020 esophageal biopsy specimens obtained between 1975 and 1981 in patients with symptoms of gastroesophageal reflux were reviewed. Barrett's esophagus was identified in 84 patients (8 percent). The 362 patients seen between 1980 and 1981 were reviewed in detail. The symptoms in patients with Barrett's esophagus differed from those of the patients without Barrett's esophagus. Dysphagia was more often present in the former group (34 percent versus 16 percent, p less than 0.05) and epigastric distress was less frequent (11 percent versus 27 percent, p less than 0.05). Objective findings of hiatal hernia, esophageal stricture, and esophageal ulcers occurred more commonly in patients with Barrett's esophagus than in those without Barrett's esophagus (70 percent versus 48 percent, 31 percent versus 4 percent, and 14 percent versus 6 percent, respectively, p less than 0.05). Mid esophageal strictures were associated almost exclusively with Barrett's esophagus (five of six patients). At esophagoscopy, erythema was seen more commonly with Barrett's esophagus. The diagnosis was suspected by the endoscopist in only 34 percent of patients subsequently demonstrated histopathologically to have Barrett's esophagus. There was no significant difference in the prevalence of a positive Bernstein test result or gastroesophageal reflux on upper gastrointestinal series in patients with and without Barrett's esophagus. However, a hypotensive lower esophageal sphincter was found more commonly in patients with Barrett's esophagus (100 percent versus 53 percent, p less than 0.05). Thirteen of the 84 patients with Barrett's esophagus (15 percent) had a coexistent adenocarcinoma arising from Barrett's mucosa. These patients, when compared with the patients with Barrett's esophagus without carcinoma, were more often male (77 percent versus 51 percent, p = 0.1), more often had dysphagia (69 percent versus 34 percent, p less than 0.05), and more frequently had a comparatively short duration of symptoms (67 percent versus 36 percent, p less than 0.05). Our findings suggest that patients with Barrett's esophagus have a high risk of development of carcinoma. Because the entity is often not recognized at endoscopy, routine esophageal biopsy should be performed on all patients undergoing esophagoscopy for symptoms of gastroesophageal reflux. Patients with known Barrett's esophagus should be followed closely with repeated endoscopy and biopsy.

Entities:  

Mesh:

Year:  1985        PMID: 3966636     DOI: 10.1016/s0002-9610(85)80031-3

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  46 in total

1.  Cytochromes P450 are expressed in proliferating cells in Barrett's metaplasia.

Authors:  S J Hughes; M A Morse; C M Weghorst; H Kim; P B Watkins; F P Guengerich; M B Orringer; D G Beer
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

Review 2.  Barrett's esophagus: environmental influences in the progression of dysplasia.

Authors:  Ralph A Boulton; Bernhard Usselmann; Imtiyaz Mohammed; Janusz Jankowski
Journal:  World J Surg       Date:  2003-07-28       Impact factor: 3.352

Review 3.  Barrett's oesophagus--to screen or not to screen?

Authors:  M Atkinson
Journal:  Gut       Date:  1989-01       Impact factor: 23.059

4.  The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high-grade dysplasia.

Authors:  M J Edwards; D R Gable; A B Lentsch; J D Richardson
Journal:  Ann Surg       Date:  1996-05       Impact factor: 12.969

5.  Comparison of reflux esophagitis and its complications between African Americans and non-Hispanic whites.

Authors:  Kenneth J Vega; Sian Chisholm; M Mazen Jamal
Journal:  World J Gastroenterol       Date:  2009-06-21       Impact factor: 5.742

Review 6.  Barrett's esophagus and esophageal adenocarcinoma: the scope of the problem.

Authors:  M S Levine; J B Herman; E E Furth
Journal:  Abdom Imaging       Date:  1995 Jul-Aug

7.  Barrett's esophagus in children and adolescents without neurodevelopmental or tracheoesophageal abnormalities: a prospective study.

Authors:  Dang M Nguyen; Hashem B El-Serag; Mitchell Shub; Mark Integlia; Louise Henderson; Peter Richardson; Kenneth Fairly; Mark A Gilger
Journal:  Gastrointest Endosc       Date:  2011-02-26       Impact factor: 9.427

8.  Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model.

Authors:  R C Fitzgerald; M B Omary; G Triadafilopoulos
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

9.  Polymorphisms of glutathione S-transferase M1, T1 and P1 in patients with reflux esophagitis and Barrett's esophagus.

Authors:  Zdenek Kala; Jiří Dolina; Filip Marek; Lydie Izakovicova Holla
Journal:  J Hum Genet       Date:  2007-05-03       Impact factor: 3.172

10.  Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults.

Authors:  A Chak; T Lee; M F Kinnard; W Brock; A Faulx; J Willis; G S Cooper; M V Sivak; K A B Goddard
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.